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what Have we Learnt about BCG 
vaccination in the Last 20 Years?
Hazel M. Dockrell* and Steven G. Smith
Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene and 
Tropical Medicine, London, United Kingdom
A number of new tuberculosis (TB) vaccines have been or are entering clinical trials, 
which include genetically modified mycobacteria, mycobacterial antigens delivered by 
viral vectors, or mycobacterial antigens in adjuvant. Some of these vaccines aim to 
replace the existing BCG vaccine but others will be given as a boosting vaccine following 
BCG vaccination given soon after birth. It is clear that the existing BCG vaccines provide 
incomplete and variable protection against pulmonary TB. This review will discuss what 
we have learnt over the last 20 years about how the BCG vaccine induces specific and 
non-specific immunity, what factors influence the immune responses induced by BCG, 
and progress toward identifying correlates of immunity against TB from BCG vaccination 
studies. There is still a lot to learn about the BCG vaccine and the insights gained can 
help the development of more protective vaccines.
Keywords: BCG, vaccination, tuberculosis, efficacy, biomarkers, correlates of protection, immune responses, 
infants
iNTRODUCTiON
The BCG vaccine has been used since 1921 to prevent tuberculosis (TB) and is considered to be the 
world’s most widely used vaccine (1). Yet, it is well established that the protective efficacy of BCG 
varies depending in which geographical location it is administered and we understand very little 
about why it protects when it does, or why it fails to protect when it does not. This review will survey 
what we have learnt about BCG over the last 20 years. Although a lot of progress has been made, the 
past two decades have shown that there is no simple correlate of BCG-induced protection against 
TB even though T-cells and IFNγ are clearly required.
We still need to understand why BCG gives such variable protection against pulmonary TB in 
different settings. The BCG vaccine remains critical for the development of new TB vaccines, many 
of which will be given as a booster vaccine after BCG vaccination, and any factors that affect how 
BCG works may also impact on these as well as on new genetically modified BCG vaccines or other 
live mycobacterial vaccines (2, 3).
Neonatal BCG provides good protection against disseminated and pulmonary TB disease 
in young children (4) but variable efficacy against pulmonary TB in adults when given later 
in life. However, when it does protect, this protection can be long-lived, lasting for up to 15 years in 
the United Kingdom (5), 30–40 years in Norway (6), and even as long as 50–60 years in Alaska (7). 
There is also evidence from outbreak settings to support the hypothesis that BCG vaccination can 
protect against infection, as well as disease; for example, an association has been observed between 
the presence of a BCG scar and not only less disease but also lower rates of interferon-gamma release 
assay (IGRA) positivity with relative risks for vaccinated compared with unvaccinated children of 
0.61 for infection and 0.51 for disease (8).
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Over the last 20  years most of the world’s children have 
continued to receive BCG immediately after birth or when 
they are first in contact with health services. In 2005, the 
United Kingdom, which had previously vaccinated adolescents, 
switched to a targeted vaccination of infants at higher risk of 
infection (i.e., with parents or grandparents born in high inci-
dence countries or who live in areas of the United Kingdom 
where the annual incidence of TB exceeds 40/100,000). Other 
countries have never given BCG, in order to retain the use of 
the tuberculin skin test (or the newer IGRA tests) as a means 
of assessing infection or because the risk of infection is low (9). 
BCG scars are often the best indication of prior vaccination that 
is available, but are an imperfect proxy for prior vaccination 
particularly if infants are vaccinated after birth (10).
Vaccination of young infants can, however, lead to dis-
seminated BCGosis if the infant is HIV-infected (11). For this 
reason, the Global Committee on Vaccine Safety recommended 
that BCG vaccine should not be given to infants who were HIV 
infected. As HIV status is generally not known and as even in 
areas with higher HIV infection rates, most mothers will be on 
antiretroviral treatment, and their infants given post exposure 
prophylaxis, most infants are still being vaccinated without test-
ing. As well as acquired immunodeficiencies, inherited genetic 
disorders of the immune system also confer susceptibility on 
infants to disseminated BCG infection following vaccination as 
well as to childhood TB [reviewed in detail here (12)]. A safer 
BCG for use in immunocompromised infants would therefore 
be beneficial.
wHAT HAve we LeARNT ABOUT THe 
CAUSeS OF vARiABLe PROTeCTiON 
iNDUCeD BY BCG OveR THe LAST 
20 YeARS?
Pre-Sensitization with environmental 
Mycobacteria
BCG vaccination immediately or shortly after birth provides 
consistent protection against the disseminated forms of TB in 
young children (4, 13, 14), and is very cost effective (15). Neonatal 
BCG also protects against pulmonary TB in children (4) which 
contrasts with the variable protection seen against pulmonary TB 
in adolescents and young adults (16).
BCG vaccination is more protective against pulmonary 
disease in children and adults at higher latitudes and in those 
screened for prior sensitization by mycobacteria (4, 17). 
Environmental mycobacterial are often assumed to be the 
culprits, mycobacteria species that survive in different environ-
mental niches, and colonize humans over time (18). The impact 
of prior sensitization, as detected by tuberculin skin testing, on 
the protective efficacy of BCG against pulmonary TB has been 
shown in a number of settings (4) but not whether this induces 
masking of the BCG vaccine effect (inducing protection that 
BCG cannot improve upon) or blocking (inducing pre-existing 
immune responses that prevent BCG vaccine-induced, protec-
tive responses) (19). One reason for limited progress has been 
the lack of antigens specific for environmental mycobacteria 
with which to dissect T-cell responses to the different mycobac-
teria other than tuberculosis or non-tuberculous mycobacteria 
(NTM; e.g., Mycobacterium avium) (20). Skin test positivity to 
Mycobacterium tuberculosis purified protein derivative (PPD or 
tuberculin) increases with age, although indurations >10 mm 
are less frequent in those who are BCG vaccinated (21). It is 
widely assumed that the effects of environmental mycobacteria 
or NTM would precede BCG vaccination, perhaps blocking 
BCG multiplication (22, 23); however, this is unlikely for infants 
vaccinated soon after birth, and too little work has focused on 
their effects post-BCG. In the mouse model, oral dosing with 
NTMs following BCG vaccination decreased protection (24).
BCG Strain variations
Genetic variability between the different BCG vaccine strains 
might explain variable protection. The original attenuated 
Mycobacterium bovis bacille Calmette Guerin was kept in culture 
for many years before it was properly conserved and seed lots 
were preserved by lyophilization. It was distributed to different 
locations worldwide where further culture resulted in what are 
now known as BCG Russia, Japan, Copenhagen, etc. Improved 
sequencing methods have shown that further genetic events have 
occurred in these strains, including additional genetic deletions 
(25, 26). Although some countries have only used one strain 
of BCG, in others, two or more strains have been used making 
analysis difficult (27). The different vaccine strains induce varying 
degrees of T-cell response in in vitro peripheral blood mononu-
clear cell (PBMC) cultures from those vaccinated with different 
BCG vaccine strains (19, 28). However, to date there has been no 
evidence that such genetic variation between strains accounts for 
variability in efficacy or that the protection given by a particular 
BCG vaccine strain is related to the year in which the study was 
performed (4).
Route of Administration
BCG vaccine is delivered most often by the intradermal route. 
It can be given percutaneously by a multi-puncture device rather 
than intradermally but a large study in South Africa showed both 
delivery routes were equally protective (29, 30). Most data describ-
ing the impact of administration route on vaccine efficacy has 
come from animals. Originally BCG was given orally and studies 
in guinea pigs have shown that BCG can be as protective and 
with less pathology induced post-infection if given BCG is given 
orally (31). Giving both a BCG prime and an MVA85A boost to 
mice intranasally induced much more effective protection than 
seen using other routes of immunization (32), and more recently 
there is renewed interest in the mucosal route of vaccination (33). 
In rhesus macaques, improved BCG-induced protection was 
observed when the vaccine was administered endobronchially 
into the lungs when compared with parenteral vaccination (34).
There is also a body of data on the effect of administration 
route on the quantity and quality of the immune response 
induced. Percutaneous and intradermal routes induced similar 
immunogenicity in a study in South Korea (35). Giving BCG fol-
lowed by the ID93 vaccine in GLA adjuvant intranasally induced 
tissue resident T-helper (Th)-17 T-cells rather than Th-1 T-cell 
immunity (36) and when BCG itself was given by the mucosal 
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route, this resulted in effector memory and resident memory 
T-cells in the mouse lung (37).
vaccine Batch variations
There have also been questions about viability or growth rate vari-
ations in different batches of vaccine, which are only required to 
have colony forming units between set limits (and thus may also 
contain varying numbers of dead bacilli). A study in West Africa 
found that batches of BCG showing slower growth were associ-
ated with larger BCG scars, and a higher prevalence of positive 
PPD skin test responses in the Mantoux skin test (38). Issues of 
batch or vaccine strain variability are very challenging to study 
at scale, as the EPI program will ship vaccine from one of several 
suppliers and thus, as mentioned above, many regions can have 
used three or more types of vaccine (9, 27), as well as different 
batches of the same vaccine strain.
Global Differences in Non-Specific 
Protection?
There has been interest in the benefits of administering BCG for 
reasons other than as a vaccine against TB for many years. For 
example, BCG vaccine can be instilled into the bladder where it is 
an effective immunotherapy against non-muscle invasive bladder 
cancer (39, 40). BCG vaccination is also associated with reduced 
rates of asthma but despite a number of observational studies, 
analyzed in two meta-analyses (41, 42), there have only been two 
randomized clinical trials using neonatal BCG vaccination and 
only one trial showed some beneficial effect (43, 44).
Studies in West Africa have indicated that BCG vaccination 
may have beneficial effects on all-cause mortality in infants, 
although the effects were most marked in low birth weight infants 
(45). Until recently, these effects had not been examined in infants 
in higher income or latitude settings, so there was a lot of interest 
in a study in Copenhagen that hypothesized that giving BCG 
at birth to Danish infants would reduce the number of somatic 
infections. In 2,129 BCG vaccinated and 2,133 unvaccinated con-
trols, BCG vaccination had no effect on all-cause hospitalizations 
[hazard ratio 1.05 (95% confidence intervals 0.93–1.18)] or on 
parent-reported infections up to the age of 15 months. There was 
no difference between outcomes in normal birth weight infants 
or premature infants in this European setting (46). Some of the 
previously described non-specific effects of vaccination show sex 
differences; however, in this Danish study, there was no difference 
in outcomes by sex (46). Thus, any non-specific effects may be 
more marked in certain low and middle-income country settings.
DiSSeCTiNG iMMUNe ReSPONSeS TO 
BCG AT THe CeLLULAR AND 
MOLeCULAR LeveL
early events following vaccination
BCG is usually administered by intradermal injection. It has 
been possible, in animals, to investigate the vaccination site tis-
sue for rapid innate immune responses induced by the array of 
pathogen-associated molecular patterns BCG is endowed with. 
These are largely components of the mycobacterial cell wall such 
as peptidoglycans, arabinogalactan, and mycolic acids that inter-
act with Toll-like receptors (47) and other pattern recognition 
receptors such as complement receptor and mannose receptor as 
reviewed recently (48). The immediate response is characterized 
by inflammatory cytokines in BCG “lesions,” including IL-1β, 
TNFα, MCP-1, and IL-8, as demonstrated in rabbits. A biphasic 
pattern of expression indicated that the source of the cytokines is 
local resident innate cells (days 1–3) followed later by infiltrating 
mononuclear cells (day 9) (49). Although most studies of the 
immune response to BCG in humans focus on peripheral blood, 
punch biopsies at the vaccination site have revealed that live 
BCG persists until at least 4 weeks post-vaccination in previously 
unvaccinated adults. The cellular infiltrate at the vaccination 
site, as revealed by suction blister analysis included lymphocytes 
(CD3+) and monocytes (CD14+) but predominantly comprised 
CD15+ neutrophils (50). Interestingly, human blood neutrophils 
that have recently captured BCG mycobacteria in vitro have been 
shown to cooperate with dendritic cells to enhance antigen-
specific T-cell responses (51). Despite the chronic nature of intra-
cellular mycobacterial infections, neutrophils are also present in 
the immune response in human TB. Gene expression signatures 
associated with neutrophils were found in TB disease (52) and 
in the lungs of patients with TB, many neutrophils containing 
M. tuberculosis are present (53).
BCG lacks the esx-1 locus which, although providing sufficient 
attenuation compared with M. bovis or M. tuberculosis to allow 
its use as a vaccine, prevents phagosomal rupture, cytosolic 
contact, and host cell death following uptake by phagocytic anti-
gen presenting cells (54). As such, there are a host of cytosolic 
immune detection systems that are underused by the vaccine 
but which may represent pathways for the induction of more 
potently protective immune responses (54). Clearly, in the case of 
M. tuberculosis, some of these responses are responsible for 
enhanced virulence via increased inflammation, granuloma for-
mation, and damage to lung structure and function however there 
appears to be an esx-related balance to be struck between patho-
genicity and immunity. Recombinant BCG expressing ESX-1 from 
M. marinum had much reduced virulence in immunocom-
promised mice when compared with M. tuberculosis itself or 
BCG expressing ESX-1 from M. tuberculosis however immune 
responses and protection against M. tuberculosis challenge were 
improved when compared with BCG (55). Interestingly for the 
design of new vaccines for TB, the ESAT-6 related immune 
responses that are important for the control of M. tuberculosis 
rely, at least in part, on antigen-non-specific, IFNγ-producing 
CD8+ T-cells, and natural killer cells that are induced via the 
NLRP3-inflammasome-IL-18 pathway (56).
Adaptive immune Responses to BCG
The primary mechanism of action of BCG-induced protection 
against TB has long been thought to be Th-1 cell mediated and 
although the last 20  years have provided clues to the involve-
ment of other effector mechanisms, the Th-1 paradigm remains 
in place. Resident dendritic cells travel to local lymph nodes 
bearing antigen/live BCG and activate antigen-specific CD4+ 
T-cells in the presence of type 1 polarizing cytokines such as 
IL-12 and IL-18. IFNγ-secreting T-cells therefore represent the 
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canonical immune response to BCG vaccination (57). Despite 
robust Th-1 responses in adults following BCG, our understand-
ing of the newborn immune system dictated that an equivalent 
response to BCG would be unexpected in infants who demon-
strate a marked bias toward regulatory and Th-2 response in 
their natural reaction to microbial challenge. Surprisingly, BCG 
also proved to be a potent inducer of Th-1 responses in infants 
(58). The hypothesis that delaying BCG vaccination of infants 
might circumvent some of the more profound regulatory effects 
of the newborn immune response and lead to improved type 1 
immunity has come in for some scrutiny, however study results 
have been mixed (see below).
The antigen specificity of BCG-induced T-cells is broad, reflect-
ing the plethora of mycobacterial antigens possessed by BCG 
which are presented to the immune system (59). Dendritic cells 
that have collected BCG antigens have the ability to cross-present 
antigen and BCG-specific CD8+ T-cells are detectable following 
BCG stimulation of PBMC from BCG-vaccinated donors in vitro 
(60, 61). Improving this component of the BCG-induced vaccine 
response is one of several approaches being taken to enhance the 
immunogenicity of BCG and develop a better TB vaccine. One 
strategy has been the insertion of the Listeriolysin gene designed 
to facilitate access of BCG antigen to the endogenous antigen 
processing pathway (62); the BCG∆ureC:hly vaccine is more 
immunogenic in mice than parental BCG and induces Th-1 and 
IL-17-producing T-cells in man (63, 64). However, development 
of a recombinant BCG with a mutant Perfringolysin gene over-
expressing Ag85A, Ag85B, and Rv3407 has been discontinued as 
varicella zoster virus was reactivated in 2/8 vaccinees, although 
the vaccine was immunogenic and induced anti-mycobacterial 
activity in man (65). Another approach is the use of adenovirus 
vectors rather than MVA to deliver M. tuberculosis antigens 
following BCG vaccination in a prime-boost regimen, as adeno-
virus vectors induce a more mixed CD4 and CD8 T-cell activation 
than MVA which is better at inducing CD4 T-cell responses (66).
One of the most prominent developments in the field of 
immunology in the last 20 years has been the rise of the Th-17 
cell, initially identified in the context of autoimmune disease. 
Th-17 cell polarization is brought about by the activation of CD4+ 
T-cells in the presence of TGFβ and IL-6 and the Th-17 popula-
tion is characterized by the expression of IL-17 and IL-22. Th-17 
cells contribute to the granulomatous response to Mtb infection 
(67) and they are important for immune protection against more 
virulent, clinical isolates of M. tuberculosis (68). Th-17 cells were 
responsible for enhanced vaccine-induced protection against 
Mtb challenge in a mouse model (69, 70) and they are often taken 
as a sign of improved immunogenicity in pre-clinical models of 
novel TB vaccines. For example, the recombinant BCG vaccine 
BCG∆ureC:hly, which induces increased protection compared 
with parental BCG in mice, induces increased numbers of IL-17 
producing helper T-cells (63), with some increase in CD8 T-cells 
producing IL-17 in human vaccinees (64). BCG is not consid-
ered a potent inducer of Th-17 cells. Our group detected IL-17+ 
CD4+ T-cells following infant BCG vaccination in the United 
Kingdom but at much lower frequencies than polyfunctional 
Th-1 cells (71). One explanation for poor Th-17 responses to BCG 
may be the strain’s lack of the RD1 region as discussed above. 
The RD1-encoded ESAT-6 protein, which is absent in BCG, is 
a potent inducer of Th-17 cells which are activated following 
interactions between ESAT-6 and TLR-2. Improved protective 
efficacy is seen when BCG is complemented with the ESAT-6 
containing RD1 region; and enhanced Th-17 responses appear to 
be a component of this protection (72) as do antigen non-specific 
CD8+ and natural killer cells (see above).
B-cell and antibody responses in the context of TB have not 
been studied to the extent of their T-cell counterparts due to what 
may turn out to be an under-appreciation of their importance. 
Recent evidence suggests a role for functionally distinct antibody 
responses in latent TB infection (73, 74) and antibody and 
memory B-cell responses in BCG-vaccinated adults have been 
demonstrated (75, 76) and may correlate with a reduced risk of 
TB disease in infants (77, 78).
Despite evidence for longevity in the protective efficacy of 
BCG in some settings, this protection has yet to be attributed 
to a defined population of memory immune cells. It is difficult 
in humans to differentiate mycobacteria-specific, long-lived 
memory cells that are present because of an historic BCG vac-
cination from responses that are constantly re-stimulated by 
exposure to environmental mycobacteria. This is easier to study 
in animal models where exposure to mycobacteria is more easily 
controlled. In pre-clinical studies of the recombinant BCG vac-
cine candidate BCG∆ureC:hly in mice, there was an association 
between vaccine-induced protection and CXCR5+ CCR7+ cen-
tral memory CD4+ T-cells (79). Also, in mice, the quality of the 
T-cell response to vaccination was reliant upon the persistence 
of live BCG. Once drug-sensitive BCG bacteria were removed by 
drug treatment of mice, there was a reduction in antigen-specific 
T effector cells, and a reduction in protection (80). In man, BCG 
is still present in vaccination sites at 1 month after vaccination 
(50) but data on its longer-term survival are limited. Although 
there have been case reports of longer-term survival of BCG 
[i.e., where an HIV-infected individual developed disseminated 
BCG 30 years after vaccination (81)], disseminated BCG infec-
tions have not increased dramatically in countries where HIV 
infection is more prevalent, suggesting that in most cases BCG 
does not survive long-term in vaccinees.
BCG-induced Trained innate immunity
Although interactions between the BCG vaccine and innate 
immune system receptors such as complement receptor-3 and 
TLRs 2 and 4 were previously known (82, 83), a more recent 
discovery is the ability of BCG to bestow a type of immunologi-
cal memory on innate cells, so-called trained innate immunity 
(84, 85). Mediated by NOD2 receptor signaling and epigenetic 
modification of macrophages, the phenomenon is characterized 
by an enhanced ability of macrophages to produce cytokines 
such as TNFα and IL-6 in response to unrelated microorganisms 
and TLR ligands following BCG vaccination. Natural killer cells 
have also been demonstrated to contribute to the trained innate 
effect both in humans and in mice (86). Trained innate cells alter 
their metabolism, switching from oxidative phosphorylation to 
aerobic glycolysis (87). Trained immunity is reduced if mono-
cytes from controls are stimulated with irradiated BCG bacilli 
rather than live BCG (88). Trained innate immunity is clearly a 
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prime candidate mechanism to explain the non-specific protec-
tive effects of BCG described above. To this end, our group and 
others have investigated whether BCG vaccination of infants has 
the same effect on the innate immune response. Jensen et al. in a 
cohort of West African infants and our group in United Kingdom 
infants both showed evidence of enhanced innate responses to 
non-specific stimuli following infant BCG vaccination (89, 90).
FACTORS THAT AFFeCT BCG-iNDUCeD 
iMMUNe ReSPONSeS
vaccination Setting
As noted above BCG vaccination is less effective against pulmo-
nary TB in some settings. This phenomenon has been explored 
using immunological analysis, which confirmed that >80% of 
United Kingdom adolescents did not make an IFNγ response 
to PPD in diluted whole blood cultures before vaccination, 
whereas over 60% of Malawian adolescents and young adults 
did; 12 months post-vaccination there was still marked immuno-
logical memory present in most of the United Kingdom vaccinees 
whereas the Malawian vaccinees did not show a vaccine-induced 
enhancement of their responses (91). Less expected was the 
finding that Malawian infants, presumed to be immunologically 
naïve when vaccinated, also made lower IFNγ responses than 
United Kingdom infants (92) with reduced Th-1 and increased 
Th-2 cytokine responses (93). In the United Kingdom, BCG-
vaccinated infants show increased BCG growth inhibition 
compared with unvaccinated infants (71); similar studies have 
not yet been reported for African infants. Again, there are other 
reports where growth inhibition is not associated with BCG vac-
cination, or with protection. Although BCG-induced immunity 
can be long-lived, there was no association between childhood 
BCG vaccination and mycobacterial growth inhibition in human 
bronchoaleolar lavage cells from TB contacts as assessed by colony 
counts (94). In a study of BCG-vaccinated South African infants, 
tested at 4–6 months of age, there was no significant association 
between growth inhibition of BCG and subsequent development 
of disease (77).
A number of other explanations have been suggested for vary-
ing immunogenicity and protective efficacy of the BCG vaccine. 
There are clearly factors related to location or setting. There are 
seasonal influences that determine how T-cell responses are 
induced or maintained, as shown for IFNγ responses in Malawi 
(92). Varying vaccination schedules may affect immunogenicity, 
as shown in some studies where, when BCG vaccine was given 
with oral polio vaccine (OPV) in Guinea Bissau, IFNγ, and IL-5 
responses to PPD were reduced (95); however, any such immu-
nosuppressive effects resulting from oral live polio vaccination 
should now reduce as OPV is replaced with inactivated polio 
vaccine.
Maternal Factors
In some of these settings, many mothers will be infected with 
latent TB, and this could lead to either in utero sensitization or 
tolerization to mycobacterial antigens. However, so far LTBI 
in mothers has only been shown to have a transient effect on 
responses to mycobacterial antigens in their infants (96, 97). 
Maternal BCG scar was associated with stronger proinflamma-
tory cytokine responses to innate stimuli in infant cord blood, but 
not to stronger responses in the mothers themselves (98). Other 
maternal infections may also modulate BCG-induced immunity. 
Although infants will not acquire helminth infections until well 
after BCG vaccination, in LMIC many of their mothers will carry 
helminth infections. There was no clear association of maternal 
helminth infection with the infants immune responses to vac-
cination (99) and treating pregnant women in the second or third 
trimester with albendazole, praziquantel, or both did not affect 
infant responses to BCG, tetanus, or measles vaccination (100). 
Co-infections in the infants themselves could also modulate 
immunity. Cytomegalovirus infection is acquired early in life by 
most infants in Africa and has a profound effect on the immune 
system (101–103). Other factors could include nutrition, genet-
ics, and season of birth (104, 105).
Delayed BCG vaccination
Many infants do not receive BCG vaccination immediately after 
birth, and delays in vaccination might improve immunity, due to 
maturation of the immune system, which is skewed toward Th-2 
T-cell immune responses at birth. However, delaying BCG vacci-
nation has shown less consistent effects on BCG-induced immu-
nogenicity than might have been expected (58, 106–110). Partly 
this lack of consensus results from variations in the approaches 
taken by different studies, including the age until which vaccina-
tion is delayed, the time points post-vaccination at which blood 
samples are obtained and analyzed and the range of assays used 
and immunological functions investigated. Delayed BCG may 
circumvent the risks associated with at birth vaccination of HIV-
exposed infants. Tchakoute et al. reported that immune responses 
in HIV-exposed, uninfected infants vaccinated at 8 weeks of age 
were at least as robust as those in infants vaccinated at birth and 
in some respects (enhanced CD4 T-cell IFNγ responses and 
increase cytokine functionality in CD4 and CD8 T-cells) delayed 
vaccination was better (110). Kagina et al. demonstrated better 
T-cell cytokine responses (including polyfunctional CD4 T-cells) 
at 1 year in infants where BCG was delayed to 10 weeks of age. The 
differences detectable at an earlier time point of 10 weeks post-
vaccination were more modest which agrees with the findings of 
Ritz et al. who conducted a similar study (107, 109).
In contrast to the studies mentioned above in which delay-
ing BCG was either not different or in some cases better than 
vaccination at birth, two further studies reported that immune 
responses were enhanced in infants who received BCG at birth 
compared with those in which it was delayed. In the Gambia, 
Th-1 and Th-17 responses measured 4.5  months after vac-
cination were reduced when BCG was delayed to 4.5  months 
(approximately 19 weeks of age) however the differences became 
less apparent when samples were obtained later, at 9 months of 
age (106). In contrast Lutwama et  al. found that at 9  months 
of age it was still possible to detect better CD4 and CD8 T-cell 
cytokine responses in infants vaccinated at birth compared 
with those vaccinated at 6  weeks of age (108). In addition to 
the variables mentioned above, the different settings of all these 
studies should be noted. With the exception of the study by Ritz 
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et al., performed in Australia (109), most of these studies were 
performed in Africa, although they were located in different 
settings; some of which (Uganda and the Gambia) were more 
equatorial than others (South Africa). The same factors that 
determine the geographical variation in BCG efficacy may also 
account for differences in the effect of delayed vaccination.
TOwARD CORReLATeS OF PROTeCTiON
T-Cell and B-Cell immune Responses as 
Correlates of Protection
Although most of these studies have investigated immunogenic-
ity rather than protection, a large study based in South Africa that 
recruited 5,726 BCG-vaccinated infants and followed them for 
2 years, has enabled correlates of risk of disease to be investigated 
more directly. In this cohort, the proportion of polyfunctional 
T-cells in BCG stimulated cultures was not associated with 
reduced risk of developing TB disease (111). Despite compre-
hensive analyses using gene expression, correlates of risk could 
not be identified. The protected and unprotected infants showed 
marked heterogeneity in gene expression patterns, with distinct 
subsets in both protected and unprotected groups with higher or 
lower monocyte:lymphocyte ratios and myeloid or lymphoid cell 
activation (112) (see below). In the only other BCG-vaccinated 
infant cohort followed for protection against the development 
of disease, infants from the MVA85A vaccine trial in which the 
MVA85A vaccination following BCG had not induced significant 
efficacy (113) were assessed for biosignatures associated with 
protection or progression. T-cell activation (CD4 T-cells express-
ing HLA DR) was associated with increased risk of progression 
to disease, but BCG-induced IFNγ producing T-cells were associ-
ated with reduced risk of TB (77).
Perhaps as a response to the lack of confirmed T-cell correlates 
of protection induced by BCG vaccination, there is renewed 
interest in B-cell immunity in TB, which as noted above has been 
under-studied. Although antibodies have not provided useful 
diagnostic tests for TB, expression of B-cell-associated genes are 
modulated during TB treatment (114) and the frequencies of 
plasmablasts are increased in those with active TB disease com-
pared with healthy community controls, and community controls 
with evidence of latent TB infection have higher numbers of both 
plasmablasts and memory B cells (78). Memory B cells specific for 
PPD were higher in BCG-vaccinated adult donors than unvac-
cinated subjects, even from individuals vaccinated 13–45 years 
earlier (75). It is therefore interesting that in infants from the 
MVA vaccine trial higher concentrations of IgG antibodies to 
Ag85 at 5–7 months of age were associated with a reduced risk of 
subsequent TB (77).
Unbiased Functional Assays of  
BCG-induced Protection: Mycobacterial 
Growth inhibition
Functional assays that do not rely on prior knowledge of specific 
immune correlates of protection have been of interest for some 
time. Such assays can potentially indicate vaccine-induced pro-
tection in easily accessible samples (e.g., whole blood or PBMC) 
and are unbiased in the sense that they do not focus on any given 
immune component. Early interest in mycobacterial growth inhi-
bition as a surrogate marker of protection involved the in vitro 
expansion of lymphocytes with relevant antigens prior to incuba-
tion with BCG-infected monocytes. PBMC previously stimulated 
with mycobacterial whole cell lysate or live BCG induced infected 
monocytes to control the growth of BCG better as did previous 
BCG vaccination of donors themselves (115). In another study 
using an assay that did not rely on in vitro stimulation of PBMC, 
ex vivo whole blood or fresh PBMC from adults who were recently 
BCG vaccinated (either primary vaccination or re-vaccination) 
were incubated with live BCG and growth inhibition determined 
by Bactec MGIT analysis. The study reported that PBMC from 
adults who had received primary BCG did control mycobacterial 
growth better ex vivo than unvaccinated controls (116). In a study 
of infants vaccinated in early life (at approximately 7  weeks of 
age), our group demonstrated better PBMC-mediated growth 
inhibition of BCG in vaccinated infants compared with unvac-
cinated controls 3 months after vaccination, although the effect 
had waned by 12 months (71). Despite these positive data sup-
porting the use of mycobacterial growth inhibition as a surrogate 
marker of vaccine-induced protection, it should be noted that, 
as with vaccine-induced T-cell responses, growth inhibition was 
not associated with reduced risk of TB disease in BCG-vaccinated 
South African infants (77). The concept of mycobacterial growth 
inhibition has been taken a step further with human challenge 
models whereby protection is assessed following the administra-
tion of an in vivo mycobacterial challenge, usually an intradermal 
inoculation of live BCG (117, 118). Such an approach has allowed 
the association of in vivo control of live BCG with patterns of gene 
expression and cellular immune responses (119).
variable Profiles of Response to BCG 
vaccination: Hampering the Search for 
Correlates of Protection?
As discussed above, population differences exist in adult and 
infant immune response to BCG (91–93) however, even within 
populations, marked heterogeneity in the host response to BCG 
vaccination has been observed. South African infants who 
received BCG clustered into two groups of responders that dis-
played distinct myeloid or lymphoid activation patterns of gene 
expression (112). Furthermore, Boer and colleagues found that 
young adults receiving primary BCG vaccination responded in 
a surprisingly dichotomous manner. Either broadly proimflam-
matory responses with local reactogenicity and induction of 
polyfunctional CD4 T-cells or responses characterized by mild 
local inflammation, poor cytokine, and polyfunctional CD4 
T-cell induction and a predominance of regulatory CD8 T-cells 
were detected (120).
Although there is opportunity in the fact that BCG vaccina-
tion demonstrates protective efficacy in infants and in adults in 
some geographical locations, there are clearly some host-related 
factors that modify immune responses to BCG and give rise to 
significant heterogeneity. Until we understand these factors better 
and take them into account, it will be difficult to identify broadly 
relevant correlates of protection in BCG-vaccinated cohorts.
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CONCLUSiON
Although there has been much progress over the last 20 years, we 
are still unable to identify BCG-induced correlates of protection 
in vaccinated infants. This remains a  priority area for further 
research, as it is possible that the development of effective boost-
ing TB vaccines could be abandoned simply because we have 
yet to discover the essential aspect of BCG-induced immunity 
to TB that should be boosted. Similarly, a better understanding 
of BCG-induced correlates of protection will help novel, live 
mycobacterial vaccines avoid the pitfalls that have caused BCG 
to fail in certain settings. To date, the search for BCG-induced 
correlates has been far too simplistic. However, the advent of 
more detailed immune and memory cell phenotyping obtained 
using mass cytometry (121) and the availability of more gene 
expression datasets in recent times is providing an increasingly 
nuanced picture. Coupled with sophisticated bioinformatic 
analyses, these new approaches may soon identify the com-
plex biosignatures associated with BCG-induced protection 
against TB.
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